Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Forecast EPS for 2021

<< Previous

Bullboard Posts

Next >>

Comment by Stocker46on Dec 07, 2021 11:55am

153 Views

Post# 34206589

RE:Forecast EPS for 2021

At the current SP, the price/earnings ratio is just over 8.
It makes no sense to exclude impairment charges.
Due to the nature of their business, there have been several impairment charges in past years & they will likely continue .. which is the reason I sold a while back.

If the SP drops further, I may get back in.

<< Previous

Bullboard Posts

Next >>

Full Circle Lithium goes global with its battery fire-fighter